Dyne Therapeutics (DYN)
(Real Time Quote from BATS)
$24.32 USD
+0.63 (2.64%)
Updated Apr 26, 2024 10:16 AM ET
3-Hold of 5 3
D Value C Growth F Momentum D VGM
Dyne Therapeutics, Inc. (DYN) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$37.56 | $56.00 | $25.00 | 58.48% |
Price Target
Based on short-term price targets offered by nine analysts, the average price target for Dyne Therapeutics, Inc. comes to $37.56. The forecasts range from a low of $25.00 to a high of $56.00. The average price target represents an increase of 58.48% from the last closing price of $23.70.
Analyst Price Targets (9 )
Broker Rating
Dyne Therapeutics, Inc. currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by nine brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on eight recommendations.
Of the nine recommendations deriving the current ABR, nine are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 9 | 9 | 8 | 8 | 8 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
3/7/2024 | Guggenheim Securities | Debjit Chattopadhyay | Strong Buy | Strong Buy |
3/6/2024 | Piper Sandler | Edward A Tenthoff | Strong Buy | Strong Buy |
3/6/2024 | H.C. Wainwright & Co. | Andrew S Fein | Strong Buy | Strong Buy |
2/16/2024 | Chardan Capital Markets | Keay T Nakae | Strong Buy | Strong Buy |
1/4/2024 | Raymond James | Steven Seedhouse | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 9 |
Average Target Price | $37.56 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 89 of 252 |
Current Quarter EPS Est: | -0.80 |